NRG-GU015: The Phase III Adaptive Radiation and Chemotherapy for Muscle Invasive Bladder Cancer Trial (ARCHER)

Sponsor:

NRG

Sponsor Study ID:

NRG-GU015

CTO #:

104267

NCT Number:

NCT07097142

Phase:

III

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Bladder

Study Objectives:

Demonstrate non-inferiority of ultra-hypofractionated (SBRT) compared to hypofractionated RT with a 10% non-inferiority margin (from 50% to 40%) in the rate of bladder-intact event-free survival (BI-EFS) at 3 years (corresponding to a hazard ratio <1.32)

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)